Elicio Therapeutics (ELTX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	28.03 mm	28.03 mm	28.03 mm	28.03 mm		28.03 mm
Cash burn (monthly)	(no burn)	99.33 k	3.45 mm	3.19 mm		2.05 mm
Cash used (since last report)	n/a	277.14 k	9.62 mm	8.90 mm		5.72 mm
Cash remaining	n/a	27.75 mm	18.41 mm	19.13 mm		22.30 mm
Runway (months of cash)	n/a	279.4	5.3	6.0		10.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2023

ELTX institutional ownership history Ownership history

19.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	5	21	-76.2%
Opened positions	0	5	EXIT
Closed positions	16	0	NEW
Increased positions	0	5	EXIT
Reduced positions	0	3	EXIT

13F shares	Current	Prev Q	Change
Total value	197.79 mm	2.87 bn	-93.1%
Total shares	1.61 mm	1.92 mm	-16.5%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
GKCC	702.64 k	$70.26 mm	0.0%
Clal Biotechnology Industries	689.57 k	$6.49 mm	0.0%
Vifor	199.56 k	$2.19 mm	0.0%
Meyer Handelman	13.90 k	$115.92 mm	0.0%
Northwest Capital Management	350.00	$2.92 mm	0.0%

Largest transactions	Bought/sold	Change
Vanguard	-140.53 k	EXIT
CM Management	-65.00 k	EXIT
Nantahala Capital Management	-30.00 k	EXIT
Geode Capital Management	-27.87 k	EXIT
Millennium Management	-20.38 k	EXIT
Citadel Advisors	-16.21 k	EXIT
Bridgeway Capital Management	-12.50 k	EXIT
BAC Bank of America	-1.68 k	EXIT
Steward Partners Investment Advisory	-1.55 k	EXIT
C Citigroup	-374.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ELTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Dec 24	Peter DeMuth	Common Stock	Option exercise	Acquire M	No	No	4.41	381	1.68 k	381
16 Dec 24	Peter DeMuth	Stock Option Common Stock	Option exercise	Dispose M	No	No	4.41	381	1.68 k	0
21 Nov 24	Yekaterina Chudnovsky	Stock Option Common Stock	Grant	Acquire A	No	No	5.12	4,100	20.99 k	4,100
21 Nov 24	Allen Nissenson	Stock Option Common Stock	Grant	Acquire A	No	No	5.12	4,100	20.99 k	4,100
21 Nov 24	Robert R Ruffolo	Stock Option Common Stock	Grant	Acquire A	No	No	5.12	4,100	20.99 k	4,100
21 Nov 24	Venkatesan Jay	Stock Option Common Stock	Grant	Acquire A	No	No	5.12	4,100	20.99 k	4,100

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Elicio Therapeutics Highlights Results for ELI-002 Cancer Vaccine at ESMO

12 Dec 24

Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio"))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, presented updated results

Elicio Therapeutics Q3 2024 GAAP EPS $(1.39) Misses $(0.73) Estimate

13 Nov 24

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.73) by 90.41 percent.

Jones Trading Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $9

31 Oct 24

Jones Trading analyst Soumit Roy initiates coverage on Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $9.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

1 Oct 24